Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...
STAT28d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...
Insurers will not cover obesity drugs that will cost users €2,500-plus a year
As a result, it will be available only on private prescription at a cost of €215 or more a month. That equates to an annual ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
pharmaphorum9d
Lilly preps for rollout of its connected diabetes system
After years of preparation, Eli Lilly is on the brink of launching a ... The Tempo system brings together a pre-filled insulin pen, the TempoSmart app and a recently-approved Smart Button device ...